Compare Incyte Corporation (INCY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tapestry, Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Tapestry, Inc. trades at $116.24 (market cap $23.09B). The key difference: Incyte Corporation and Tapestry, Inc. are close in size by market cap, and Tapestry, Inc. pays a 1.6% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Tapestry, Inc. for 70 Days on average.
| INCY | TPR | |
|---|---|---|
Market Cap | $22.85B | $23.09B |
Volume | 1,927,029 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $164.78 |
52-Week Low | $83.80 | $98.81 |
Typical Hold Time | 33 Days | 70 Days |
Enterprise Value | $18.35B | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Tapestry (TPR) trades at $115.82, up 2.14% today, with strong analyst support showing 73% buy ratings and a $174.64 consensus price target. The stock demonstrates robust profitability with 77.82% gross margins and 19.09% net income margin, though recent earnings show volatility with Q3 2026 results pending. Technical indicators signal bearish momentum with price near key support at $114, while fundamentals reveal mixed trends with revenue growth projected to $8B in 2026 but net income showing significant fluctuation from $183M in 2025 to projected $1.5B in 2026.
The investment case balances strong brand positioning and international growth potential against execution risks in the Kate Spade segment and tariff pressures. With the current price representing a 34% discount to analyst targets and institutional accumulation continuing, the stock offers upside potential for patient investors willing to navigate near-term volatility and margin expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
